Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Rating of “Moderate Buy” by Brokerages

Roivant Sciences Ltd. (NASDAQ:ROIVGet Free Report) has earned an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $16.56.

Several research firms recently issued reports on ROIV. Deutsche Bank Aktiengesellschaft began coverage on Roivant Sciences in a research report on Tuesday, December 12th. They set a “buy” rating and a $14.00 target price for the company. Guggenheim cut their target price on Roivant Sciences from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, November 15th. Bank of America increased their target price on Roivant Sciences from $11.00 to $12.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 2nd. Piper Sandler began coverage on Roivant Sciences in a research report on Friday, January 5th. They set an “overweight” rating and a $20.00 target price for the company. Finally, JPMorgan Chase & Co. cut their target price on Roivant Sciences from $16.00 to $15.00 and set an “overweight” rating for the company in a research report on Tuesday, November 14th.

Check Out Our Latest Stock Report on Roivant Sciences

Insider Buying and Selling at Roivant Sciences

In other news, COO Eric Venker sold 96,950 shares of Roivant Sciences stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $10.92, for a total value of $1,058,694.00. Following the completion of the transaction, the chief operating officer now owns 532,207 shares in the company, valued at approximately $5,811,700.44. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, major shareholder Vivek Ramaswamy sold 3,000,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $11.05, for a total transaction of $33,150,000.00. Following the completion of the sale, the insider now directly owns 51,929,426 shares of the company’s stock, valued at approximately $573,820,157.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Eric Venker sold 96,950 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $10.92, for a total value of $1,058,694.00. Following the sale, the chief operating officer now directly owns 532,207 shares of the company’s stock, valued at $5,811,700.44. The disclosure for this sale can be found here. 4.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Roivant Sciences

A number of institutional investors and hedge funds have recently modified their holdings of the business. Mirabella Financial Services LLP lifted its stake in shares of Roivant Sciences by 4.1% during the 3rd quarter. Mirabella Financial Services LLP now owns 34,583 shares of the company’s stock worth $404,000 after acquiring an additional 1,362 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of Roivant Sciences by 2.7% in the 3rd quarter. American Century Companies Inc. now owns 53,923 shares of the company’s stock worth $630,000 after buying an additional 1,426 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in shares of Roivant Sciences by 42.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 5,385 shares of the company’s stock worth $60,000 after buying an additional 1,608 shares during the period. Pathstone Family Office LLC lifted its holdings in shares of Roivant Sciences by 6.1% in the 3rd quarter. Pathstone Family Office LLC now owns 38,488 shares of the company’s stock worth $124,000 after buying an additional 2,227 shares during the period. Finally, Vontobel Holding Ltd. lifted its holdings in shares of Roivant Sciences by 16.7% in the 3rd quarter. Vontobel Holding Ltd. now owns 15,782 shares of the company’s stock worth $184,000 after buying an additional 2,258 shares during the period. 64.76% of the stock is owned by institutional investors.

Roivant Sciences Stock Up 0.6 %

ROIV stock opened at $10.87 on Tuesday. Roivant Sciences has a fifty-two week low of $6.59 and a fifty-two week high of $13.24. The business’s 50-day moving average is $10.64 and its two-hundred day moving average is $10.49. The company has a debt-to-equity ratio of 0.29, a quick ratio of 5.84 and a current ratio of 5.84. The company has a market cap of $8.74 billion, a price-to-earnings ratio of -8.23 and a beta of 1.34.

Roivant Sciences (NASDAQ:ROIVGet Free Report) last posted its quarterly earnings data on Monday, November 13th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.02. Roivant Sciences had a negative return on equity of 73.04% and a negative net margin of 951.77%. The firm had revenue of $37.10 million for the quarter, compared to the consensus estimate of $26.68 million. As a group, analysts forecast that Roivant Sciences will post -1.77 earnings per share for the current year.

Roivant Sciences Company Profile

(Get Free Report

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

Further Reading

Analyst Recommendations for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.